Insider Selling: Allogene Therapeutics, Inc. (NASDAQ:ALLO) Director Sells 9,136 Shares of Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Director Deborah M. Messemer sold 9,136 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $2.18, for a total value of $19,916.48. Following the completion of the transaction, the director now directly owns 157,629 shares in the company, valued at approximately $343,631.22. The trade was a 5.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Allogene Therapeutics Price Performance

Shares of NASDAQ:ALLO traded down $0.08 during trading on Tuesday, reaching $2.19. 1,883,512 shares of the company’s stock traded hands, compared to its average volume of 2,467,694. The stock has a market capitalization of $459.18 million, a P/E ratio of -1.46 and a beta of 0.83. Allogene Therapeutics, Inc. has a 12 month low of $1.99 and a 12 month high of $5.78. The company has a 50 day moving average of $2.59 and a 200-day moving average of $2.59.

Hedge Funds Weigh In On Allogene Therapeutics

Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its holdings in shares of Allogene Therapeutics by 340.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock worth $4,073,000 after acquiring an additional 1,351,055 shares during the period. Dimensional Fund Advisors LP grew its position in Allogene Therapeutics by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock worth $5,944,000 after purchasing an additional 507,021 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Allogene Therapeutics by 70.3% during the second quarter. The Manufacturers Life Insurance Company now owns 480,381 shares of the company’s stock valued at $1,119,000 after buying an additional 198,231 shares during the last quarter. Primecap Management Co. CA raised its holdings in shares of Allogene Therapeutics by 4.1% during the second quarter. Primecap Management Co. CA now owns 5,670,226 shares of the company’s stock valued at $13,212,000 after buying an additional 221,840 shares during the last quarter. Finally, TD Asset Management Inc grew its holdings in Allogene Therapeutics by 82.7% in the 2nd quarter. TD Asset Management Inc now owns 799,340 shares of the company’s stock worth $1,862,000 after buying an additional 361,904 shares in the last quarter. 83.63% of the stock is owned by institutional investors.

Analyst Ratings Changes

ALLO has been the topic of several recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. Piper Sandler cut their target price on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Allogene Therapeutics in a research note on Friday, November 8th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Allogene Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $9.73.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).